Please login to the form below

Not currently logged in
Email:
Password:

Amarin

This page shows the latest Amarin news and features for those working in and with pharma, biotech and healthcare.

Amarin sues FDA over off-label policy

Amarin sues FDA over off-label policy

Amarin sues FDA over off-label policy. Claims block on discussing off-label uses conflicts freedom of speech. ... Amarin is in the process of carrying out a cardiovascular outcomes study called REDUCE-IT to try to support its position, with results due

Latest news

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    Aside from GSK, the launch of a lower-priced Lovaza generic in the US also impacts Amarin Pharmaceuticals' Vascepa (icosapent ethyl), another fish oil-based therapy that is already on the

  • Amarin slides as FDA panel votes against fish oil therapy Amarin slides as FDA panel votes against fish oil therapy

    Amarin slides as FDA panel votes against fish oil therapy. Advisory committee wants more data on Vascepa. ... Meanwhile, the cost of running REDUCE-IT is also a drain on Amarin's finances, with the bill for 2013 expected to come in at somewhere between

  • Senior changes for Forest and Amarin

    Olanoff, effective December 31, while Amarin Corporation has announced that Joseph S Zakrzewski, an experienced biotech executive, has been appointed as its chief executive officer, effective immediately. ... Amarin. Prior to joining Amarin, Thero was

  • Prior to joining Pharmacopeia, Liebler served as senior vice-president of strategic Planning at Questcor and held executive-level positions with Enzon, Elan, Amarin and Athena Neurosciences.

  • Malcolm's Market Eye: 8 to 14 December 2007

    Amarin buying Ester Neurosciences of Israel. Amarin, the biotechnology company, is purchasing Ester Neurosciences, an Israeli company, for up to GBP 15.8m. ... Amarin ran into trouble earlier in 2007 when late stage trials of its leading product, a

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Teva's Mark Salyer joins Amarin Teva's Mark Salyer joins Amarin

    Teva's Mark Salyer joins Amarin. Takes up newly-created chief commercial officer role. ... Amarin has appointed Mark Salyer to the newly-created position of chief commercial officer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics